Specialty Pharma Journal Specialty, Precision & Technology
AstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from the TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). The trial did not meet the primary endpoint of a statistically-significant reduction in disease activity in patients with SLE …
Tag Archives: Lupus
August, 2018
July, 2018
-
20 July
Study Published in The Lancet Shows Benefit of Baricitinib for the Treatment of Systemic Lupus Erythematosus
INDIANAPOLIS, July 19, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 study for baricitinib were published by The Lancet. The study, the first completed Phase 2 study of a JAK inhibitor in SLE, showed that a statistically …
May, 2018
-
1 May
Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Verily Life Sciences LLC, an Alphabet company, today announced a scientific collaboration using Verily’s Immunoscape platform to identify and better understand the immunological basis of three common and serious inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease …
July, 2017
-
24 July
GSK Receives FDA Approval for New Self-Injectable Formulation of Benlysta for Systemic Lupus Erythematosus
GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients with active, autoantibody‑positive SLE who are receiving standard therapy. Systemic Lupus Erythematosus (SLE) is the most common form of lupus, a chronic, incurable autoimmune …
June, 2017
-
14 June
Positive Phase 2a Safety and Efficacy Data Supports Further Development of Celgene’s Oral Lupus Drug
BOUDRY, Switzerland–(BUSINESS WIRE)–Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from the phase 2a SLE-001 trial evaluating CC-220, the Company’s investigational, oral immunomodulatory compound, at the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid. A trend toward greater improvement with CC-220 treatment compared …
January, 2017
-
30 January
Celgene to Acquire Autoimmune Disease Startup Delinia
SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) and Delinia, Inc. (“Delinia”), a privately held biotechnology company developing novel therapeutics for autoimmune diseases, today announced that they have entered into an agreement for the acquisition of Delinia by Celgene. The transaction expands Celgene’s Inflammation and Immunology pipeline through …
December, 2016
-
16 December
Investigating Kidney Biomarkers to Track Lupus
ANN ARBOR, Mich. – Lupus, a chronic autoimmune disease, can wreak havoc on an affected individual’s body through inflammation, pain and even damage of the skin, joints and organs. To try to better understand how the disease begins and progresses, researchers at the University of Michigan investigated whether kidney biomarkers …
August, 2016
-
15 August
Aurinia Pharmaceuticals’ Lupus Candidate Meets Primary Endpoint in Phase IIB Trial
VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive top-line results from the Phase 2b AURA-LV (AURA) clinical study in patients with active lupus nephritis (LN). The trial achieved its primary endpoint, …
March, 2016
-
21 March
Lupus Study Shows Precision Medicine’s Potential to Define the Genetics of Autoimmune Disease
DALLAS – March 18, 2016 – Demonstrating the potential of precision medicine, an international study based at UT Southwestern Medical Center used next-generation DNA sequencing technology to identify more than 1,000 gene variants that affect susceptibility to systemic lupus erythematosus (SLE). Precision medicine is an emerging field that aims to deliver …
November, 2015
-
11 November
AstraZeneca’s Lupus Drug Succeeds in Mid-Stage Study
AstraZeneca, along with its global biologics research and development arm, MedImmune, will present positive data today from the Phase II trial of anifrolumab for the treatment of moderate-to-severe systemic lupus erythematosus (SLE or lupus) at the American College of Rheumatology (ACR) 2015 Annual Scientific Meeting in San Francisco. Trial results …